News

KDFW2d
Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Zacks Investment Research on MSN1d
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...
Ibj.com7d
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Eli Lilly: Don't Overthink This Buying Opportunity
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...